Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Assets (2019 - 2025)

Vivos Therapeutics' Current Assets history spans 7 years, with the latest figure at $4.4 million for Q4 2025.

  • Quarterly results put Current Assets at $4.4 million for Q4 2025, down 41.34% from a year ago — trailing twelve months through Dec 2025 was $4.4 million (down 41.34% YoY), and the annual figure for FY2025 was $4.4 million, down 41.34%.
  • Current Assets for Q4 2025 was $4.4 million at Vivos Therapeutics, down from $5.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $39.4 million in Q2 2021 to a low of $2.0 million in Q3 2023.
  • The 5-year median for Current Assets is $7.4 million (2024), against an average of $11.8 million.
  • The sharpest move saw Current Assets crashed 80.15% in 2022, then surged 272.75% in 2024.
  • Year by year, Current Assets stood at $27.3 million in 2021, then crashed by 80.15% to $5.4 million in 2022, then tumbled by 54.63% to $2.5 million in 2023, then skyrocketed by 203.66% to $7.5 million in 2024, then tumbled by 41.34% to $4.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $4.4 million, $5.8 million, and $6.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.